AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
•Tie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker Business live – latest updatesBritain’s biggest drugmaker AstraZeneca is in discussions to...
•BMS, headquartered in Princeton and known for its cancer treatments, is worth $133bn.
هذا الخبر من The Guardian. خبر يقدم أدوات ذكاء اصطناعي للتلخيص والترجمة والاستماع.
المصدر: The Guardian | Source: The GuardianTie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker
Britain’s biggest drugmaker AstraZeneca is in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group.
AstraZeneca, run by longtime chief executive Pascal Soriot, is the second-biggest listed company in the UK, with a market value of nearly £196bn. BMS, headquartered in Princeton and known for its cancer treatments, is worth $133bn.
Continue reading...
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة The Guardian. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by The Guardian. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
